AbbVie's Elahere Cuts Death Risk By 32%, Shows Consistent Survival Benefit In Long-Term Analysis For Certain Ovarian Cancer Patients

AbbVie Inc (NYSE:ABBV) released on Saturday the final analysis of the confirmatory Phase 3 MIRASOL trial of Elahere (mirvetuximab soravtansine-gynx) in women with folate receptor alpha (FRα)-positive platinum-resistant ovarian cancer (PROC) compared to chemotherapy.

The U.S. Food and Drug Administration granted full approval to Elahere in March 2024, and the European Commission approved the drug in November 2024.

At 30.5 months median follow-up, treatment with Elahere continued to show significant improvements ...